menu
    • menu
    [{"orgOrder":0,"company":"AnaBios","sponsor":"Orion Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"ORM-11372","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AnaBios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AnaBios \/ Orion","highestDevelopmentStatusID":"4","companyTruncated":"AnaBios \/ Orion"},{"orgOrder":0,"company":"AnaBios","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"ANB-504","moa":"Dual sodium channels","graph1":"Neurology","graph2":"IND Enabling","graph3":"AnaBios","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AnaBios \/ NIH","highestDevelopmentStatusID":"5","companyTruncated":"AnaBios \/ NIH"}]

    Find Clinical Drug Pipeline Developments & Deals by AnaBios

    Menu

    AnaBios

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AnaBios

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            AnaBios

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANB-504

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : National Institutes of Health

                            Deal Size : $1.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NIH/NINDS Awards AnaBios With $1.7M Grant to Develop Novel Analgesic for Mixed Inflammatory, Neuropathic Pain ...

                            Details : This award will support the execution of Investigational New Drug-enabling studies aimed at obtaining Food and Drug Administration approval for subsequent human dosing in a Phase 1 clinical study incliding ANB-504, a lead small molecule dual inhibitor of...

                            Brand Name : ANB-504

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 30, 2021

                            Lead Product(s) : ANB-504

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : National Institutes of Health

                            Deal Size : $1.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AnaBios

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            AnaBios

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORM-11372

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Orion Biotechnology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AnaBios and Orion Publish Scientific Article Describing Novel Cardiac Compound

                            Details : AnaBios provided ex vivo data from human heart tissue to assess the pro-arrhythmic risk of the new NCX1.1 inhibitor, ORM-11372 (developed in Orion Pharma).

                            Brand Name : ORM-11372

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            October 29, 2020

                            Lead Product(s) : ORM-11372

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Orion Biotechnology

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth